ReviewPLoS neglected tropical diseases2017
Melioidosis: Clinical impact and public health threat in the tropics.
Review in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 81 citations in OpenAlex.
- Global animal melioidosis prevalence: a systematic review and meta-analysis.Irish veterinary journal · 2026Article
- Geographical distribution of Burkholderia pseudomallei in Taiwanese croplands and the influence of bacterial community interactions on its incubation viability.PLoS neglected tropical diseases · 2025Article
- Analysis of Burkholderia pseudomallei IspF in complex with sulfapyridine, sulfamonomethoxine, ethoxzolamide and acetazolamide.Acta crystallographica. Section F, Structural biology communications · 2025Article
- Geographical mapping and seroprevalence of Burkholderia pseudomallei amongst livestock species in Lao People's Democratic Republic.PLoS neglected tropical diseases · 2025Article
- Combatting melioidosis with chemical synthetic lethality.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Imaging and clinical manifestations of hematogenous dissemination in melioidosis.BMC medical imaging · 2024Article
- Effectiveness of UmoniumBMC infectious diseases · 2024Article
- Risk Factors for Melioidosis Mortality and Epidemics: A Multicentre, 10-Year Retrospective Cohort Study in Northern Hainan.Infectious diseases and therapy · 2023Article
- In silico designing of a multi-epitope vaccine against Burkholderia pseudomallei: reverse vaccinology and immunoinformatics.Journal, genetic engineering & biotechnology · 2022Article
- Andrographolide stabilized-silver nanoparticles overcome ceftazidime-resistant Burkholderia pseudomallei: study of antimicrobial activity and mode of action.Scientific reports · 2022Article
- Shenqi Yanshen Formula (SQYSF) protects against chronic kidney disease by modulating gut microbiota.Bioengineered · 2022Article
- Structural and biophysical characterization of the Burkholderia pseudomallei IspF inhibitor L-tryptophan hydroxamate.Bioorganic & medicinal chemistry letters · 2021Article
- Osteomyelitis and Septic Arthritis Due toFrontiers in cellular and infection microbiology · 2021Article
- Hijacking of the Host's Immune Surveillance Radars byFrontiers in immunology · 2021Review
- Pediatric osteomyelitis due to rare tropical multi-drug resistance (MDR) organisms: a treatment quandary.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Article
- Article
- Genomic loss in environmental and isogenic morphotype isolates of Burkholderia pseudomallei is associated with intracellular survival and plaque-forming efficiency.PLoS neglected tropical diseases · 2020Article
- Prolonged intermittent fever and massive splenomegaly in a miner working in the tropical jungle, China.PLoS neglected tropical diseases · 2020Article
- Melioidosis DS rapid test: A standardized serological dipstick assay with increased sensitivity and reliability due to multiplex detection.PLoS neglected tropical diseases · 2020Article
- Retraction: Melioidosis: Clinical impact and public health threat in the tropics.PLoS neglected tropical diseases · 2020Article
Corrections and comments
- Retraction · 2020-07-01Concerns/Issues about Referencing/Attributions · Error in Analyses · Error in Data · Error in Results and/or Conclusions · Error in Text · · see also: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007123
- Commented on by
- Retracted
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review briefly summarizes the geographical distribution and clinical impact of melioidosis, especially in the tropics. Burkholderia pseudomallei (a gram-negative bacterium) is the major causative agent for melioidosis, which is prevalent in Singapore, Malaysia, Thailand, Vietnam, and Northern Australia. Melioidosis patients are increasingly being recognized in other parts of the world. The bacteria are intrinsically resistant to many antimicrobial agents, but prolonged treatment, especially with combinations of antibiotics, may be effective. Despite therapy, the overall case fatality rate of septicemia in melioidosis remains significantly high. Intracellular survival of the bacteria within macrophages may progress to chronic infections, and about 10% of patients suffer relapses. In the coming decades, melioidosis will increasingly afflict travelers throughout many global regions. Clinicians managing travelers returning from the subtropics or tropics with severe pneumonia or septicemia should consider acute melioidosis as a differential diagnosis. Patients with open skin wounds, diabetes, or chronic renal disease are at higher risk for melioidosis and should avoid direct contact with soil and standing water in endemic regions. Furthermore, there are fears that B. pseudomallei may be used as a biological weapon. Technological advancements in molecular diagnostics and antibiotic therapy are improving the disease outcomes in endemic areas throughout Asia. Research and development efforts on vaccine candidates against melioidosis are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.